Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847695 | 1.00 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19TP53TDP1 | |
| SCHEMBL262483 | 0.81 | POLB (0.43) | CYP3A4CYP2C9CYP2C19TP53TDP1 | |
| SCHEMBL28817638 | 0.81 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19TP53TDP1 | |
| SCHEMBL1052265 | 0.79 | POLB (0.40) | CYP3A4CYP2C9CYP2C19TDP1GAA | |
| SCHEMBL3107682 | 0.78 | SMPD1 (0.42) | — | |
| SCHEMBL5100575 | 0.78 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL24165690 | 0.77 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19TP53TDP1 | |
| SCHEMBL8199890 | 0.77 | GAA (0.44) | CYP3A4CYP2C9CYP2C19TP53TDP1 | |
| SCHEMBL14671697 | 0.75 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19TP53TDP1 | |
| SCHEMBL27816008 | 0.75 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | PHOSPHO1, G6PC1, PC | CYP3A4 1604/4885CYP2C9 1928/4885CYP2C19 1676/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | CYP3A4 1604/4885CYP2C9 1928/4885CYP2C19 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.